RNA-seq of comprehensively examine variations in MHCC-97H cells treated with various doses of lenvatinib at the transcriptomic level.

To determine the drug target of lenvatinib, RNAseq was used to evaluate the transcriptome differences between lenvatinib-treated MHCC-97H cells and their parental counterparts.Results show that SERPINE1 may be direct target of lenvatinib, and AKR1C1 have potential prognostic significance in the prediction of LR(lenvatinib-resistant) in HCC. AKR1C1 could be a promising therapeutic target for patients with LR-type liver cancer. Overall design: MHCC-97H cells treated with 40, 60, 80, and 100 µM lenvatinib, and RNAseq was used to evaluate the transcriptome differences between lenvatinib-treated MHCC-97H cells and their parental counterparts.For more information, please consult [e-mail]为明确仑伐替尼（lenvatinib）的药物作用靶点，本研究采用RNA测序（RNAseq）分析仑伐替尼处理的MHCC-97H细胞与其亲本细胞之间的转录组差异。研究结果显示，SERPINE1可能是仑伐替尼的直接作用靶点，而AKR1C1在预测肝细胞癌（HCC）仑伐替尼耐药（LR，lenvatinib-resistant）患者的预后中具有潜在临床价值。AKR1C1或可成为仑伐替尼耐药型肝癌患者的潜在治疗靶点。整体实验设计：采用40、60、80、100 µM浓度的仑伐替尼处理MHCC-97H细胞，通过RNA测序比较经仑伐替尼处理的细胞与亲本细胞的转录组差异。如需获取更多相关信息，请致邮[e-mail]